Sensus Healthcare, Inc. (NASDAQ:SRTS) Shares Acquired by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP lifted its position in shares of Sensus Healthcare, Inc. (NASDAQ:SRTS - Free Report) by 30.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 378,568 shares of the company's stock after buying an additional 88,953 shares during the quarter. Dimensional Fund Advisors LP owned approximately 2.31% of Sensus Healthcare worth $2,620,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Renaissance Technologies LLC grew its holdings in shares of Sensus Healthcare by 5.3% during the fourth quarter. Renaissance Technologies LLC now owns 430,934 shares of the company's stock worth $2,982,000 after buying an additional 21,600 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its position in shares of Sensus Healthcare by 81.2% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 150,150 shares of the company's stock worth $1,039,000 after acquiring an additional 67,269 shares during the last quarter. Marshall Wace LLP boosted its position in shares of Sensus Healthcare by 99.6% in the fourth quarter. Marshall Wace LLP now owns 132,286 shares of the company's stock worth $915,000 after acquiring an additional 65,994 shares during the last quarter. O Shaughnessy Asset Management LLC boosted its position in shares of Sensus Healthcare by 65.1% in the fourth quarter. O Shaughnessy Asset Management LLC now owns 93,248 shares of the company's stock worth $645,000 after acquiring an additional 36,785 shares during the last quarter. Finally, Ritholtz Wealth Management boosted its position in shares of Sensus Healthcare by 65.3% in the fourth quarter. Ritholtz Wealth Management now owns 51,261 shares of the company's stock worth $355,000 after acquiring an additional 20,256 shares during the last quarter. 25.30% of the stock is currently owned by hedge funds and other institutional investors.

Sensus Healthcare Price Performance

SRTS stock traded down $0.02 during midday trading on Tuesday, reaching $4.72. 21,506 shares of the company's stock traded hands, compared to its average volume of 211,123. The company has a market capitalization of $77.77 million, a P/E ratio of 11.74 and a beta of 1.30. Sensus Healthcare, Inc. has a fifty-two week low of $4.01 and a fifty-two week high of $9.33. The business has a 50-day moving average price of $4.61 and a two-hundred day moving average price of $6.10.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last announced its quarterly earnings results on Thursday, May 15th. The company reported ($0.16) earnings per share for the quarter, missing analysts' consensus estimates of $0.04 by ($0.20). The business had revenue of $8.34 million for the quarter, compared to analyst estimates of $7.23 million. Sensus Healthcare had a net margin of 15.90% and a return on equity of 12.60%. As a group, research analysts forecast that Sensus Healthcare, Inc. will post 0.32 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

SRTS has been the topic of several research analyst reports. Maxim Group decreased their target price on shares of Sensus Healthcare from $14.00 to $10.00 and set a "buy" rating on the stock in a research report on Monday. Lake Street Capital decreased their target price on shares of Sensus Healthcare from $18.00 to $13.00 and set a "buy" rating on the stock in a research report on Tuesday, March 11th. Finally, HC Wainwright reissued a "buy" rating and issued a $12.00 target price on shares of Sensus Healthcare in a research report on Friday, April 4th.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.